Literature DB >> 17389476

Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.

Sheila K West1, Beatriz Munoz, Harran Mkocha, Charlotte Gaydos, Thomas Quinn.   

Abstract

PURPOSE: The World Health Organization recommends mass treatment of trachoma-hyperendemic communities, but there are scant empiric data on the number of rounds of treatment that are necessary for sustainable reductions. The rates of active trachoma and infection with C. trachomatis were determined in a community 3.5 years after two rounds of mass treatment with azithromycin.
METHODS: Maindi village in Tanzania received a first round of mass treatment with azithromycin after a baseline survey for trachoma and infection. All residents aged 6 months and older were offered single-dose treatment with azithromycin (excluding pregnant women with no clinical trachoma, who were offered topical tetracycline). The residents were followed over an 18-month period, and, according to similar treatment criteria, were offered retreatment at 18 months. Five years after baseline (3.5 years after the second round of mass treatment), a new census and survey of current residents for trachoma and infection was conducted. Children are the sentinel markers of infection and trachoma in communities, so data are presented specifically for ages 0 to 7 years (preschool age) and 8 to 16 years.
RESULTS: Treatment coverage was above 80% for all ages in the first round, and highest (90%) in preschool-aged children. Second-round coverage was lower, <70%, and 70% in preschool-aged children. At 5 years, trachoma rates were still lower than baseline, ranging from 45% in those aged 0 to 3 years to 8% in those aged 11 to 15 years (compared with 81% and 39% at baseline, respectively). Infection rates at baseline ranged from 71% to 57%, but were 27% to 17% at 5 years after two rounds of mass treatment. At 5 years, there were no differences in trachoma or infection rates, when comparing new residents who came after the second mass treatment with those who had been resident in the village during both rounds (P > 0.05). Infection rates were lower in those who had been treated twice or at 18 months than in those treated only at baseline or never treated.
CONCLUSIONS: Although mass treatment appears to be associated with lower disease and infection rates in the long term, trachoma and C. trachomatis infection were not eliminated in this trachoma hyperendemic village 3.5 years after two rounds of mass treatment. Continued implementation of the SAFE strategy in this environment is needed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17389476     DOI: 10.1167/iovs.06-0625

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  29 in total

1.  Adverse events after mass azithromycin treatments for trachoma in Ethiopia.

Authors:  Berhan Ayele; Teshome Gebre; Jenafir I House; Zhaoxia Zhou; Charles E McCulloch; Travis C Porco; Bruce D Gaynor; Paul M Emerson; Thomas M Lietman; Jeremy D Keenan
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

2.  The medical exclusion of an immigrant to the United States of America in the early twentieth century. The case of Cristina Imparato.

Authors:  Pascal James Imperato; Gavin H Imperato
Journal:  J Community Health       Date:  2008-08

3.  Gender and performance of community treatment assistants in Tanzania.

Authors:  Alexander Jenson; Catherine Gracewello; Harran Mkocha; Debra Roter; Beatriz Munoz; Sheila West
Journal:  Int J Qual Health Care       Date:  2014-07-14       Impact factor: 2.038

4.  Cohort and age effects of mass drug administration on prevalence of trachoma: a longitudinal study in rural Tanzania.

Authors:  Nakul Shekhawat; Harran Mkocha; Beatriz Munoz; Charlotte Gaydos; Laura Dize; Thomas C Quinn; Sheila K West
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-11       Impact factor: 4.799

5.  Risk of trachoma in a SAFE intervention area.

Authors:  Assegid Aga Roba; Daksha Patel; Marcia Zondervan
Journal:  Int Ophthalmol       Date:  2012-10-10       Impact factor: 2.031

Review 6.  Chlamydial infection during trachoma monitoring: are the most difficult-to-reach children more likely to be infected?

Authors:  Jeremy D Keenan; J Moncada; T Gebre; B Ayele; M C Chen; S N Yu; P M Emerson; N E Stoller; C E McCulloch; B D Gaynor; J Schachter
Journal:  Trop Med Int Health       Date:  2011-11-28       Impact factor: 2.622

7.  Elimination of active trachoma after two topical mass treatments with azithromycin 1.5% eye drops.

Authors:  Abdou Amza; Pablo Goldschmidt; Ellen Einterz; Pierre Huguet; Celine Olmiere; Philippe Bensaid; Lucienne Bella-Assumpta
Journal:  PLoS Negl Trop Dis       Date:  2010-11-23

8.  Targeting antibiotics to households for trachoma control.

Authors:  Isobel M Blake; Matthew J Burton; Anthony W Solomon; Sheila K West; María-Gloria Basáñez; Manoj Gambhir; Robin L Bailey; David C W Mabey; Nicholas C Grassly
Journal:  PLoS Negl Trop Dis       Date:  2010-11-02

Review 9.  Strategies to control trachoma.

Authors:  Anu A Mathew; Angus Turner; Hugh R Taylor
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

10.  Importance of coverage and endemicity on the return of infectious trachoma after a single mass antibiotic distribution.

Authors:  Takele Lakew; Wondu Alemayehu; Muluken Melese; Elizabeth Yi; Jenafir I House; Kevin C Hong; Zhaoxia Zhou; Kathryn J Ray; Travis C Porco; Bruce D Gaynor; Thomas M Lietman; Jeremy D Keenan
Journal:  PLoS Negl Trop Dis       Date:  2009-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.